Fresenius Invests to Help Humacyte Develop Implantable Blood Vessels
Fresenius has invested an additional $25 million in Humacyte Inc, to help the implantable vessel company get market approval. The new vessels, which can be used to create and repair vascular accesses, are now being tested in a clinical trial for use in dialysis.
Read the full article » | Posted 09-14-2021
- Outset Medical Beat Q2 Wall Street Projections Posted 09-14-2021
- Diality Appoints Chief Business Officer Posted 08-12-2021
- FMC-NA Names Joe Turk New President for Renal Therapies Group Posted 08-12-2021
- Quanta Receives $245M Investment for SC+ Home HD System Posted 07-12-2021